Navigating the Complexities of Next-Generation Endocrine Therapy in HR+ Breast Cancer

Navigating the Complexities of Next-Generatio...

AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)

Up next

Day 5: Top Takeaways From ASCO26

Dr. Monty Pal shares highlights from the final day of ASCO26, including new research on treating anemia in myelofibrosis, advances in RAS-mutated mCRC, novel therapies for AML, and a potentially practice-changing trial in TNBC. LINK TO FULL TRANSCRIPT 

 . 9min 35sec
Day 4: Top Takeaways From ASCO26

Dr. Monty Pal shares highlights from Day 4 of the 2026 ASCO Annual Meeting, including a much-anticipated study in hepatocellular carcinoma, new data in non–small cell lung cancer, and a key update in the treatment of Merkel cell carcinoma. LINK TO TRANSCRIPT 

 . 8min 45sec

Recommended Episodes

Endocrine and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer – Capivasertib-Fulvestrant: Rapid Guideline Update
ASCO Guidelines

Dr. Angela DeMichele, Dr. Lynn Henry, and Dr. Harold Burstein present the latest breast cancer rapid recommendation update impacting two ASCO guidelines. This update focuses on the new option, capivasertib plus fulvestrant, for patients with hormone receptor-positive, HER2-negati ...  Show more

 . 14min 9sec
Systemic Therapy for Advanced HER2-Positive Breast Cancer Guideline Update
ASCO Guidelines

An interview with Dr. Sharon Giordano from the University of Texas MD Anderson Cancer Center in Houston, TX, and Dr. Nancy Davidson from Fred Hutchinson Cancer Research Center and the University of Washington in Seattle, WA, co-chairs on "Systemic Therapy for Advanced HER2-Positi ...  Show more

 . 13min 34sec
Testing for ESR1 Mutations to Guide Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer Rapid Recommendation Update
ASCO Guidelines

Dr. Angie DeMichele and Dr. Lynn Henry present the latest rapid recommendation impacting two ASCO guidelines. This update focuses on testing for ESR1 mutations in patients with hormone receptor-positive, HER2-negative metastatic breast cancer, and presents treatment recommendatio ...  Show more

 . 10min 42sec
Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer Rapid Recommendation Update
ASCO Guidelines

Dr. Beverly Moy is back on the ASCO Guidelines Podcast to discuss the latest guideline rapid recommendation update regarding sacituzumab govitecan for patients with hormone receptor-positive HER2-negative metastatic breast cancer based on recent evidence published in TROPiCS-02. ...  Show more

 . 7min 7sec